Patents by Inventor Josef George Heuer

Josef George Heuer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NEUREGULIN-4 COMPOUNDS AND METHODS OF USE
    Publication number: 20220112255
    Abstract: The present invention relates to neuregulin (NRG) 4 compounds and methods of treatment with NRG4 compounds.
    Type: Application
    Filed: December 22, 2021
    Publication date: April 14, 2022
    Inventors: Jonathan Wesley Day, Josef George Heuer, Avinash Muppidi, Wei Ni, James David Pancook
  • Neuregulin-4 compounds and methods of use
    Patent number: 11242370
    Abstract: The present invention relates to neuregulin (NRG) 4 compounds and methods of treatment with NRG4 compounds.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: February 8, 2022
    Assignee: Eli Lilly and Company
    Inventors: Jonathan Wesley Day, Josef George Heuer, Avinash Muppidi, Wei Ni, James David Pancook
  • NEUREGULIN-4 COMPOUNDS AND METHODS OF USE
    Publication number: 20200354421
    Abstract: The present invention relates to neuregulin (NRG) 4 compounds and methods of treatment with NRG4 compounds.
    Type: Application
    Filed: March 31, 2020
    Publication date: November 12, 2020
    Inventors: Jonathan Wesley Day, Josef George Heuer, Avinash Muppidi, Wei NI, James David Pancook
  • Antibodies that bind TGF-alpha and epiregulin
    Patent number: 8613921
    Abstract: The present invention provides antibodies that bind human TGF-alpha and human Epiregulin and are characterized as having high affinity, selective, and strong neutralizing properties. The antibodies are useful in the treatment of diabetic nephropathy.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: December 24, 2013
    Assignee: Eli Lilly and Company
    Inventors: Catherine Brautigam Beidler, Josef George Heuer, Ramona Judita Petrovan
  • ANTIBODIES THAT BIND TGF-ALPHA AND EPIREGULIN
    Publication number: 20120258109
    Abstract: The present invention provides antibodies that bind human TGF-alpha and human Epiregulin and are characterized as having high affinity, selective, and strong neutralizing properties. The antibodies are useful in the treatment of diabetic nephropathy.
    Type: Application
    Filed: March 28, 2012
    Publication date: October 11, 2012
    Applicant: ELI LILLY AND COMPANY
    Inventors: Catherine Brautigam Beidler, Josef George Heuer, Ramona Judita Petrovan